These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34735321)

  • 1. Dupilumab-Induced Facial Flushing After Alcohol Consumption.
    Brownstone ND; Reddy V; Thibodeaux Q; Myers B; Chan S; Liao W; Bhutani T
    Cutis; 2021 Aug; 108(2):106-107. PubMed ID: 34735321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol flushing during dupilumab therapy: An emerging adverse event.
    Napolitano M; Potestio L; Fabbrocini G; Patruno C
    Dermatol Ther; 2021 Sep; 34(5):e15064. PubMed ID: 34275182
    [No Abstract]   [Full Text] [Related]  

  • 3. Facial and neck erythema associated with dupilumab treatment: A systematic review.
    Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM
    J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
    Agnihotri G; Shi K; Lio PA
    Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
    Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
    Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Salman A; Apti Sengun Ö; Aktas M; Taşkapan O
    Dermatol Ther; 2022 Jan; 35(1):e15192. PubMed ID: 34743366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
    Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
    JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series.
    Ruiz-Villaverde R; Dominguez-Cruz J; Armario-Hita JC; Martinez-Pilar L; Alcantara-Luna S; Pereyra-Rodriguez JJ
    Dermatol Ther; 2019 Jul; 32(4):e12931. PubMed ID: 30980485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

  • 12. Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020.
    Martinez-Cabriales SA; Kirchhof MG; Constantinescu CM; Murguia-Favela L; Ramien ML
    Am J Clin Dermatol; 2021 Jul; 22(4):443-455. PubMed ID: 34076879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
    Ahn J; Lee DH; Na CH; Shim DH; Choi YS; Jung HJ; Simpson EL
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2140-2152. PubMed ID: 35695074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
    Bortoluzzi P; Ferrucci S; Galimberti D; Garavelli F; Pozzo Giuffrida F; Pizzati A; Marzano AV; Mapelli C
    Br J Dermatol; 2022 Jan; 186(1):186-187. PubMed ID: 34431510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angioedema: A potential complication of dupilumab in atopic dermatitis.
    Fritz AL; Lacy FA; Morrell DS
    Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.